					ATTY, DOCKET NO.		- 1	APPLICATION NO	D.	
					1		- 1			
OIP	<b></b> -				P-4901 09/606,909					
5	EIST C	F REFERENCES CITE	D BY APPLIC	CANT	APPLICANT					
V7	5	(Use several sheets if n	necessary)		Petits, Ronald e	t al.				
OCT 2 8 200	S .Z)				FILING DATE			GROUP		
- 0	- <u>/</u>				June 29, 2000			3748		
BADEMARY	<u>~</u>		U.S	. PATENT DOCUM	MENTS					
'EXAMINER INTIAL		COCUMENT NUMBER	DATE		NAME		CLASS	SUBCLASS	FILIN IF APPE	DATE OPRIATE
	t —						3.		1	
				· · · · · · · · · · · · · · · · · · ·					╁	
			FORE	IGN PATENT DOC	UMENTS				<u> </u>	
		DOCUMENT NUMBER	CATE		COUNTRY		CLASS	SUBCLASS	TRAN	LATION
	ļ								YES	NO
									<u> </u>	_
	<u> </u>									
			.,					L	L	
		OTHER RE	FERENCES (In	cluding Author, Tit	e, Date, Pertinent	Pages, Etc.)				
		0	DE 0	FR Methods fo	or in Vitro Percu	ıtaneous Abs	orntion	Studies		nal
RS	١.,	Bronaugh RL, Stewart	Rr, Congaon	Cit. Micaioao i			Oiption	Ottuaics.	II. Anii	IIai
BT	АА	Bronaugh RL, Stewart Models for Human Skir						Oldules.	II. Anii	IIai
		1 -	n. Toxicol and	Applied Pharm	acol. 1982 Mar	15;62(3):481	1-8.			
断	AA AB	Models for Human Skir	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar	15;62(3):481	1-8.			
		Models for Human Ski Corbo M, Liu JC, Chier	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar	15;62(3):481	1-8.			
		Models for Human Ski Corbo M, Liu JC, Chier	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar	15;62(3):481	1-8.			
		Models for Human Ski Corbo M, Liu JC, Chier	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar	15;62(3):481	1-8.			
		Models for Human Ski Corbo M, Liu JC, Chier	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar	15;62(3):481	1-8.			
		Models for Human Ski Corbo M, Liu JC, Chier	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar d Delivery of Pr	15;62(3):481 ropranolol fro	1-8. m a Mu	ultilaminate		
		Models for Human Ski Corbo M, Liu JC, Chier	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar d Delivery of Pr	15;62(3):481	1-8. m a Mu	ultilaminat		
		Models for Human Skii Corbo M, Liu JC, Chien Device. Pharm Res. 19	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar d Delivery of Pr	15;62(3):481	1-8. m a Mu	ultilaminat		
		Models for Human Skii Corbo M, Liu JC, Chien Device. Pharm Res. 19	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar d Delivery of Pr	15;62(3):481	1-8. m a Mu	ultilaminat		
		Models for Human Skii Corbo M, Liu JC, Chien Device. Pharm Res. 19	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar d Delivery of Pr	15;62(3):481 ropranolol fro	1-8. m a Mu	ultilaminat		
		Models for Human Skii Corbo M, Liu JC, Chien Device. Pharm Res. 19	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar d Delivery of Pr	15;62(3):481	1-8. m a Mu	ultilaminat		
		Models for Human Skii Corbo M, Liu JC, Chien Device. Pharm Res. 19	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar d Delivery of Pr	15;62(3):481	1-8. m a Mu	ultilaminat		
		Models for Human Skii Corbo M, Liu JC, Chien Device. Pharm Res. 19	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar d Delivery of Pr	15;62(3):481	1-8. m a Mu	ultilaminat		
		Models for Human Skii Corbo M, Liu JC, Chien Device. Pharm Res. 19	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar d Delivery of Pr	15;62(3):481	1-8. m a Mu	ultilaminat		
		Models for Human Skii Corbo M, Liu JC, Chien Device. Pharm Res. 19	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar d Delivery of Pr	15;62(3):481	1-8. m a Mu	ultilaminat		
		Models for Human Skii Corbo M, Liu JC, Chien Device. Pharm Res. 19	n. Toxicol and n YW. Transd	Applied Pharm ermal Controlle	acol. 1982 Mar d Delivery of Pr	15;62(3):481	1-8. m a Mu	ultilaminat		
	AB	Models for Human Skii Corbo M, Liu JC, Chien Device. Pharm Res. 19	n. Toxicol and n YW. Transd 989 Sep.6(9):7	Applied Pharm	acol. 1982 Mar d Delivery of Pr	15;62(3):481	/E[ 002	ultilaminate		

NOV 1 2 2002

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Papework Reduction Act of 1995, no persons are required to respond to a collection of thormation unless to comissing a valid OMB of number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

				U.S. PATENT DOCUM	MENTS	
Examiner Initials *	Cite No.1	U.S. Patent Docum	ode <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Peges, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	2,619,962		Rosenthal	12/02/1952	
	AB	3,814,097		Ganderton et al.	06/04/1974	
	AC	3,964,482		Gerstel et al.	06/22/1976	
	AD	4,270,537		Romaine	06/02/1981	
	AE	4,592,753		Panoz	06/03/1986	
	AF	5,003,987		Grinwald	04/02/1991	
	AG	5,098,389		Cappucci	03/24/1992	
	AH	5,156,591		Gross et al.	10/20/1992	
	Al	5,250,023		Lee et al.	10/05/1993	
	AJ	5,279,544		Gross et al.	01/18/1994	
	AK	5,417,662		Hjertman et al.	05/23/1995	m
	AL	5,527,288		Gross et al.	06/18/1996	오 그
	AM	5,591,139		Lin et al.	01/07/1997	S S III
	AN	5,801,057		Smart et al.	09/01/1998	5 2 O
	AO	5,820,622		Gross et al.	10/13/1998	9
	AP	5,848,991		Gross et al.	12/15/1998	S 111
	AQ	5,876,582		Frazier	03/02/1999	
	AR	5,879,326		Godshall et al.	03/09/1999	
	AS	5,928,207		Pisano et al.	07/27/1999	# 2 111
	AT	5,957,895		Sage et al.	09/28/1999	<b>S D</b>
	AU	5,997,501		Gross et al.	12/07/1999	
	AV	6,099,504		Gross et al.	08/08/2000	
	AW	6,334,856	Bı	Allen et al.	01/01/2002	
	AX	6,346,095	BI	Gross et al.	02/12/2002	

Examiner	Cite	For	eign Patent Do	cument	Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials*	No. <sup>1</sup>	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T.
	AY	CA	2 349 431		Canada	05/25/2000		
	AZ	EP	1 086 718	Al	Europe	03/28/2001		
	BA	EP	1 086 719	Al	Europe	03/28/2001		
	BB	EP	1 088 642	Al	Europe	04/04/2001		
	BC	EP	1 092 444	Al	Europe	04/18/2001		
	BD	wo	96/17648		PCT	06/13/1996		
	BE	wo	96/37155		PCT	11/28/1996		
	BF	wo	96/37256		PCT	11/28/1996		
	BG	wo	99/43350		PCT	09/02/1999		
	BH	wo	99/64580		PCT	12/16/1999		
	Bl	wo	00/67647		PCT	11/16/2000		
	BJ	wo	00/74763	A2	PCT	12/14/2000		
	BK	wo	02/11669	A2	PCT	02/14/2002		

e type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are require stitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of 2

Complete if Known					
Application Number	09/606,909				
Filing Date	June 29, 2000				
First Named Inventor	PETTIS et al.				
Group Art Unit	3748				
Examiner Name	Binh Q. TRAN				
Attorney Docket Number	D 4001				

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, seral, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	BL	E. AUTRET et al., Therapie 1991, 46 : 5-8,	
	вм	BRESSOLLE et al., "A Weibull Distribution Model for Intradermal Administration of Ceftazadime", Journal of Pharmaceutical Sciences, Vol. 82, No. 11, November 1993, pps. 1175-1178.	
	BN	HENRY et al., "Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery", Journal of Pharmaceutical Sciences, Vol. 87, No. 8, August 1998, pps. 922-925.	
	во	KAUSHIK et al., "Transdermal Protein Delivery Using Microfabricated Microneedles", Oct/Nov 1999 (1 page).	
	BP	BURKOTH et al., "Transdermal and Transmucosal Powered Drug Delivery", Critical Review <sup>TM</sup> in Therapeutic Drug Carrier Systems, 16 (4), (1999), pps. 331-384.	
	BQ	MCALLISTER et al., "Three-Dimensional Hollow Microneedle and Microtube Arrays", Conference: Solid-State Sensors and Actuators Transducers-Conference, 1999; 10th, Vol. 12, pp 1098-1103.	
	BR	MCALLISTER et al., "Solid and Hollow Microneedles for Transdermal Protein Delivery", Proceed. Int'l. Symp. Control. Rel. Bioact. Mater., 26 (Revised July 1999) Controlled Release Society, Inc. pp. 192-193	
	BS	SEBASTIEN et al., "Microfabricated Needles: A Novel Approach to Transdermal Drug Delivery", Journal of Pharmaceutical Sciences, Vol. 87, No. 8, August 1998, pp. 922-925	
		RECEIVED	
		NOV 1 3 2002	
		TECHNOLOGY GENDER H3700	
		TECHNOLOGY GENTER H3/99	

Signature Considered EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

2/5/2013

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner

/Phillip Gray/

PTO/SB/08A (10-01) r use through 10/31/2002. OMB 0651-0031 ffice: U.S. DEPARTMENT OF COMMERCE

rk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Substitute for form 1449A/PTO

Sheet

Complete if Known					
Application Number	09/606,909				
Filing Date	June 29, 2000				
First Named Inventor	Pettis, et al.				
Art Unit	3748				
Examiner Name	Binh Q. Tran				
Attorney Docket Number	P-4901				

				U.S. PAT	ENT DOCUMENTS	
Examiner Initials	Cite No.1	Number	Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Rolevant Passages or Relevant Figures Appear
_	AA -	US4,886,499		12/12/1989	Cirelli, et al.	
		US-				
-		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-	-			
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		us-				

				FOR	EIGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Office	Foreign Patent Do	Kind <sup>8</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T¢.
Br	AB	EP	0 429 842	BI	08/28/1996	Europe		
1	AC	wo	94/23777		10/27/1994	PCT		
	AD	wo	97/21457		6/19/1997	PCT R	-()ETVEL	7
¥	AE	wo	00/09186		2/24/2000	PCT		
		_					DEC 2 3 2002	
						TECH	IOLOGY CENTER R	700
-		Н						$\vdash$

Examiner Signature	BINH TRAN	Date Considered	01/05/03	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (option-a). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

The reference has been cited in 2TO-892.

PTO/SB/08B (10-01)
PTO/SB/08B (10-01)
Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Tradehard Office: U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

of

/PEVA

Sheet

Examiner

Signature

 Complete if Known

 Application Number
 09/606,909

 Filing Date
 June 29, 2000

 First Named Inventor
 Petits, et al.

 Group Art Unit
 3748

 Examiner Name
 Binh Q. Tran

 Attorney Docket Number
 P-4901

caminer   Cite   item (book, manazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s)   T-		_	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
AF Phosphorothioates in Mice*, Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 7595-7599, September 1991 Medical Sciences  AG AUTRET, et al., "Comparison of Pharmacokinetics and tolerance of Calcitopinia administered by intradermal or Subcutaneous Route*, Fundamental Clinical Pharmacology, Vol. 3, No. 2, pp 170-171, 1989  BENONI, et al., "Distribution of Ceftazidime in Ascitic Fluid", Antimicrobial Agents and Chemotherapy, Vol. 25, No. 6, June 1984, pp. 760-763  All Vol. 25, No. 6, June 1984, pp. 760-763  BICKERS, et al., editors, "Clinical Pharmacology of Skin Disease", pp. 57-90, Churchill Livingstone, Inc., 1984  BICCC, et al., "The Lymphatic Route. IV. Pharmacolinetics of Human Recombinant Interferon 22 and 1984 pp. 103-110 Elsevier Science Publishers B.V. (Biomedical Division)  CALLEN, "Intralesional Corticosteriods", Journal of the American Academy of Dermatology, University of Louisville School of Medicine, pp. 149-151, 1981  AL COSSUM, et al., "Disposition of the C-Labeled Phosphorothioate Oligonucleotide. ISIS 2105 after Intravenous Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 113-1190, Vol. 267, No. 3, 1993  COSSUM, et al., "Pharmacokinetics of C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105 after Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 89-94, Vol. 269, No. 1, 1994  CROOKE, et al., "A Pharmacokinetic Evaluation of C-Labeled Afoviren Sedium in Patients with Genital Warts", Clinical Pharmacology & Therapeutics, pp. 64-1646, Vol. 56, No. 6, Part 1, December 1994  FIROOZ, et al., "Benefits and Risks of Intralesional Corticosteroid Injection in the Treatment of Dermatology, Blackwell Science Ltd., September 1993  GOODARZI, et al., "Organ Distribution and Stability of Phosphorothioated Oligodeoxyribonucleotides in 1992  DEC 2 3 2002	xaminer nitials*		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cily and/or country where published.	T²
AG Intradermal or Subcutaineous Route*, Fundamental Clinical Pharmacology, Vol. 3, No. 2, pp 170-171, 1989  AH BENONI, et al., "Distribution of Ceffazidime in Ascitic Fluid*, Antimicrobial Agents and Chemotherapy, Vol. 23, No. 6, June 1984, pp. 760-763  AI BENONI, et al., "Distribution of Ceffazidime in Ascitic Fluid*, Antimicrobial Agents and Chemotherapy, Vol. 23, No. 6, June 1984, pp. 760-763  AI BICKERS, et al., editors, "Clinical Pharmacology of Skin Disease*, pp. 57-90, Churchill Livingstone, Inc., 1984  AI BICKERS, et al., editors, "Clinical Pharmacology of Skin Disease*, pp. 57-90, Churchill Livingstone, Inc., 1984  BICKERS, et al., editors, "Clinical Pharmacology of Skin Disease*, pp. 57-90, Churchill Livingstone, Inc., 1984  AI BICKERS, et al., "The Lymphatic Route. IV. Pharmacology of Skin Disease*, pp. 57-90, Churchill Livingstone, Inc., 1984  AI BICKERS, et al., "Disposition of Lower Pharmacology and Experimental Journal of Pharmacology, University of Louisville School of Medicine, pp. 149-151, 1981  COSSUM, et al., "Disposition of the C-Labeled Phosphorothioate Oligonucleotide. ISIS 2105 after Intravenous Administration to Rats*, The Journal of Pharmacology and Experimental Therapeutics, pp. 1915 and 19	BT	AF	Phosphorothioates in Mice", Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 7595-7599, September 1991 Medical	
AH Vol. 25, No. 6, June 1984, pp. 760-763  AI BICKERS, et al., editors, "Clinical Pharmacology of Skin Disease", pp. 57-90, Churchill Livingstone, Inc., 1984  BICKERS, et al., editors, "Clinical Pharmacology of Skin Disease", pp. 57-90, Churchill Livingstone, Inc., 1984  BICKERS, et al., "The Lymphatic Route, IV. Pharmacokinetics of Human Recombinant Interferon a2 and Natural Interferon B Administred Intradermally in Rabbits", International Journal of Pharmacokinetics, 32, 1986, pp. 103-110 Elsevier Science Publishers B.V. (Biomedical Division)  ALLEN, "Interleaved Science Publishers B.V. (Biomedical Division)  ALLEN, "Interleaved Science Publishers B.V. (Biomedical Division)  ALLEN, "Interleaved Publishers B.V. (Biomedical Division)  COSSUM, et al., "Disposition of the C-Labeled Phosphorothioate Oligonucleotide ISIS 2105 after Intravenous Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 1131-1190, Vol. 267, No. 3, 1993  AM COSSUM, et al., "Pharmacokinetics of C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105 after Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 89-94, Vol., 269, No. 1, 1994  COSSUM, et al., "Pharmacokinetic Evaluation of C-Labeled Afovirsen Sodium in Patients with Genital Warts", Clinical Pharmacology & Therapeutics, pp. 641-646, Vol. 56, No. 6, Part 1, December 1994  CROOKE, et al., "A Pharmacokinetic Evaluation of C-Labeled Afovirsen Sodium in Patients with Genital Warts", Clinical Pharmacology & Therapeutics, pp. 641-646, Vol. 56, No. 6, Part 1, December 1994  CROOKE, et al., "A Pharmacokinetic Evaluation of C-Labeled Afovirsen Sodium in Patients with Genital Warts", Clinical Pharmacology & Therapeutics, pp. 641-646, Vol. 56, No. 6, Part 1, December 1994  CROOKE, et al., "A Pharmacokinetic Evaluation of C-Labeled Afovirsen Sodium in Patients with Genital Warts", Clinical Pharmacokinetic Evaluation of C-Labeled Afovirsen Sodium in Patients with Genital Warts", Clinical Pharmacokinetic Evaluation of C-Labeled A	1	AG	AUTRET, et al., "Comparison of Pharmacokinetics and tolerance of Calcitonine administered by Intradermal or Subcutaneous Route", Fundamental Clinical Pharmacology, Vol. 3, No. 2, pp 170-171, 1989	
Al 1984  DOCCI, et al., "The Lymphatic Route. IV. Pharmacokinetics of Human Recombinant Interferon a2 and Natural Interferon 8 Administered Intrademally in Rabbits". International Journal of Pharmacoutics, 32, 1986, pp. 103-110 Elsevier Science Publishers B.V. (Biomedical Division)  CALLEN, "Intralesional Corticosteriods", Journal of the American Academy of Dermatology, University of Lower Laboratory of Callery, "Intralesional Corticosteriods", Journal of the American Academy of Dermatology, University of Lower Laboratory of Callery, "Intradesional Corticosteriods", Journal of the American Academy of Dermatology, University of Laboratory of Laboratory of Dermatology, University of Laboratory of Laboratory of Dermatology, University of Dermatology, Un	.1	ΑН	BENONI, et al., "Distribution of Cefazidime in Ascitic Fluid", Antimicrobial Agents and Chemotherapy, Vol. 25, No. 6, June 1984, pp. 760-763	
1986, pp. 103-110 Elsevier Science Publishers B.V. (Homedical Division)		AI	BICKERS, et al., editors, "Clinical Pharmacology of Skin Disease", pp. 57-90, Churchill Livingstone, Inc., 1984	-
AK Louisville School of Medicine, pp. 149-151, 1981  AL COSSUM, et al., "Disposition of the C-Labeled Phosphorothioate Oligonucleotide ISIS 2105 after Intravenous Administration to Ratis", The Journal of Pharmacology and Experimental Therapeutics, pp. 1181-1190, Vol. 267, No. 3, 1992  COSSUM, et al., "Pharmacokinetics of C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105 after Administration to Ratis", The Journal of Pharmacology and Experimental Therapeutics, pp. 89-94, Vol. 269, No. 1, 1994  CROOKE, et al., "A Pharmacokinetic Evaluation of C-Labeled Afovirsen Sodium in Patients with Genital AN Warts", Clinical Pharmacology & Therapeutics, pp. 641-646, Vol. 56, No. 6, Part I, December 1994  FIROOZ, et al., "Benefits and Risks of Intralesional Corticosteroid Injection in the Treatment of Demaafological Diseases", pp. 363-370, Vol. 20, No. 5, Clinical and Experimental Demaafology, Blackwell Science Ltd, September 1995  GOODARZI, et al., "Organ Distribution and Stability of Phosphorothioated Oligodeoxyribonucleasides in Linguistics & Drug Disposition, pp. 221-227, Vol. 13, No. 3, John Wiley & Sans Ltd & April 1992  DEC 2 3 2002	9 E	ιίλ	BOCCI, et al., "The Lymphatic Route. IV. Pharmacokinetics of Human Recombinant Interferon a2 and Natural Interferon B Administered Intradermally in Rabbits", International Journal of Phamaceutics, 32, 1986, pp. 103-110 Elsevier Science Publishers B. V. (Biomedical Division)	
COSUM, et al., "Pharmacokinetics of C-Labeled Phosphorothioate Olignucleotide, ISIS 2105 after Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 89-94, Vol 269, No. 1, 1994  CROOKE, et al., "A Pharmacokinetic Evaluation of C-Labeled Afovirsen Sodium in Patients with Genital Warts", Clinical Pharmacology & Therapeutics, pp. 641-496, Vol. 56, No. 6, Part 1, December 1994  FIROOZ, et al., "Benefits and Risks of Intralesional Corticosteroid Injection in the Treatment of Dermatological Diseases", pp. 363-370, Vol. 20, No. 5, Clinical and Experimental Dermatology, Blackwell Science Ltd, September 1995  GOODARZI, et al., "Organ Distribution and Stability of Phosphorothioated Oligodeoxyribonucleoxides in Linguistics, Biopharmaceutics & Drug Disposition, pp. 221-227, Vol. 13, No. 3, John Wiley Science Ltd, April 1992  DEC 2 3 2002	·	AK	CALLEN, "Intralesional Corticosteriods", Journal of the American Academy of Dermatology, University of Louisville School of Medicine, pp. 149-151, 1981	
Administration to Rats*, The Journal of Pharmacology and Experimental Therapeutics, pp. 89-94, Vol. 269, No. 1, 1994  AN CROOKE, et al., "A Pharmacokinetic Evaluation of C-Labeled Afovirsen Sodium in Patients with Genital Warts*, Clinical Pharmacology & Therapeutics, pp. 641-646, Vol. 56, No. 6, Part 1, December 1994  FIROOZ, et al., "Benefits and Risks of Intralesional Corticosteroid Injection in the Treatment of Dermatological Diseases" pp. 363-370, Vol. 20, No. 5, Clinical and Experimental Dermatology, Blackwell Science Ltd, September 1995  GOODARZI, et al., "Organ Distribution and Stability of Phosphorothioated Oligodeoxyribonucleosides in 1992  GOODARZI, et al., "Organ Distribution and Stability of Phosphorothioated Oligodeoxyribonucleosides in 1992  DEC 2 3 2002	-	AL	COSSUM, et al., "Disposition of the C-Labeled Phosphorothioate Oligonucleotide ISIS 2105 after Intravenous Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 1181-1190, Vol. 267, No. 3, 1993	
AN Warts*, Clinical Pharmacology & Therapeutics, pp. 641-646, Vol. 56, No. 6, Part 1, December 1994  FIROOZ, et al., "Benefits and Risks of Intralesional Corticosteroid Injection in the Treatment of Dermatological Diseases", pp. 363-370, Vol. 20, No. 5, Clinical and Experimental Dermatology, Blackwell Science Ltd, September 1995  GOODARZI, et al., "Organ Distribution and Stability of Phosphorothioated Oligodeoxyribonucleotides in Mice, Biopharmaceutics & Drug Disposition, pp. 221-227, Vol. 13, No. 3, John Wiley & San Ltd, April 1992  DEC 2 3 2002		ам -	Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, pp. 89-94, Vol	
Dermatological Diseases", pp. 363-370, Vol. 20, No. 5, Clinical and Experimental Dermatology, Blackwell Science Ltd, September 1995  GOODARZI, et al., "Organ Distribution and Stability of Phosphorothioated Oligodeoxyribonucleoxides in Ldd, April 1992  AP.  DEC 2 3 2002		AN	CROOKE, et al., "A Pharmacokinetic Evaluation of C-Labeled Afovirsen Sodium in Patients with Genital Warts", Clinical Pharmacology & Therapeutics, pp. 641-646, Vol. 56, No. 6, Part 1, December 1994	
AP 1992 DEC 2 3 2002		AO	FIROOZ, et al. "Benefits and Risks of Intralesional Corticosteroid Injection in the Treatment of Dermatological Diseases", pp. 363-370, Vol. 20, No. 5, Clinical and Experimental Dermatology, Blackwell Science Lid, September 1995	
DEC 2.3 2004	$\bigvee$	AP	<b>N</b> LO2	Þ
TECHNOLOGY CENTERIA			DEC 2 3 2004	Ĺ.,
			TOUNDIOGY CENTER	143

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

BIM TRAN

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional)
<sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
App of for use through 10/31/2002, OMB 0651-0031
d Traderack Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trade of Office: U.S. EPARTMENT OF COMMERCE U.S. Patent and Trade of Office: U.S. EPARTMENT OF COMMERCE er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

Substitute for form 1449B/PTO

3

Sheet

Examiner

Signature

7		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	Т					
xaminer nitials*	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-lasue number(s), publisher, city and/or country where published.	T2					
B5	HAYNES, et al., "Ultra-long-duration Local Anesthesia Produced by Injection of Lecithin-coated Methoxyflurane Microdroplets", Anestheiology, Vol. 63, No. 5, pp. 490-499, Nov. 1985							
1	AR	JAKOBSON, et al., "Variations in the Blood Concentration of 1, 1, 2-Trichloroethane by Percutaneous Absorption and Other Routes of Administration in the Guinea Pig", Vol. 41, No. 5, pp. 497-506, Acta Pharmacologica . et Toxicologica, November 1977						
	AS	JARRATT, et al., "The Effects of Intradermal Steriods on the Pituitary-Adrenal Axis and the Skin", The Journal of Investigative Dermatology, Vol. 62, No. 4, pp. 463-466, 1974	Ī					
	ÀT .	KIRKPATRICK, et al., "Local Anesthetic Efficacy of Methoxyflurane Microdroplets in Man", Vol. 67, No. 3A, Anesthesiology, September 1987	Ī					
	AU	LEROY, et al., "Pharmacokinetics of Ceftazidime in Normal and Uremic Subjects", Antimicrobal Agents and Chemotherapy, Vol. 25, No. 5, pp. 638-642, May 1984						
	ΑV	MCGUGAN, et al., "Adrenal Suppression from Intradermal Triancinolone", The Journal of Investigative Dermatology, Vol. 40, pp. 271-272, Baltimore, MD., 1963						
	AW	SCOTT, et al., "Toxicity of Interferon", Vol. 282, pp. 1345-1348, British Medical Journal, April 25, 1981	T					
	AX	SUPERSAXO, et al., "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", Pharmaceutical Research, Vol. 5, No. 8, pp. 472-476, August 1988	T					
	AY	SUTHEREST, "Treatment of Pruritus Vulvae by Multiple Intradermal Injections of Alcohol. A Double-Blind Study, Vol. 86, pp. 371-373, British Journal of Obstetrics and Gynecology, May 1979						
	ΑZ	WARD, et al., "Pruritus Vulvae: Treatment by Multiple Intradermal Alcohol Injections", Vol. 93, No. 2, pp. 201-204, British Journal of Dermatology, August 1975						
$\forall$	ВА	WU, et al., "Pharmacokinetics of Methoxyflurane after its Intra-Dermal Injection as Lecithin-Coated Microdroplets", Vol. 9, pp. 1-12, Journal of Controlled Release, July 1989.	I					
		DEC 2 3 2002						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Civile Information Office, Patent and Trademick, Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01) if for use through 10/31/2002, OMB 0651-0031 it Office: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trade

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE

Complete if Known **Application Number** 09/606,909 Filing Date June 29, 2000 First Named Inventor Pettis, et al. Group Art Unit 3748 Examiner Name Binh O. Tran

STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet of Attorney Docket Number P-4901 OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the

## item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Initials\* No.1 ZAYNOUN, et al., "The Effect of Intracutaneous Glucocorticoids on Plasma Cortisol Levels", Vol. 88, No. 2, pp. 151-156, British Journal of Dermatology, February 1973 вв RECEIVED DEC @ % 2002 TECHNOLOGY CENTER R3700

Examiner Signature	BINH TRAN	Date Considered	91/05/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademick, Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.